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1. Introduction
This chapter presents the current state of prostate cancer epidemiology and compares data
from different regions. The data are taken from several sources:
Globocan 2008 [1] gives a glance on the worldwide situation in cancer epidemiology and
permits the comparison of more and less developed regions in every continent.
The “Surveillance, Epidemiology and End Results” Program (SEER) [2] in the USA and the
Robert Koch Institute (RKI) [3] in Germany present epidemiologic data of highly industrial‐
ized nations with maximally developed medical systems.
The Munich Cancer Registry (MCR) [4], a population-based clinical cancer registry of Upper
Bavaria, an area of 4.5 million inhabitants in the South of Germany, presents detailed analy‐
ses of clinical data, distributions of prognostic factors and therapy, and survival analyses.
Data of the MCR have also contributed to the publication “Cancer Incidence in Five Conti‐
nents, Volume IX” [5].
2. Incidence and mortality
In Table 1 absolute numbers and age-standardized rates of incidence and mortality are pre‐
sented for selected regions and countries [1]. In 2008 it was estimated that nearly every sev‐
enth case of male malignoma was prostate cancer (899 thousand new cases, 13.6% of the
total). Therefore, in men prostate cancer was the second most diagnosed cancer after lung
cancer. Approximately three quarters of these cases were diagnosed in more developed
countries. The highest incidence rates were measured in Australia, New Zealand, Northern
and Western Europe and Northern America. Moderate incidence rates were found in South
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America and Eastern Europe. The lowest incidence rates were reported from South-Central
Asia.
Region
Incidence
absolute
Incidence
ASR (W)
Mortality
absolute
Mortality
ASR (W)
World 899 27.9 258 7.4
More developed regions 644 61.7 136 10.5
Less developed regions 255 11.9 121 5.6
Asia 133.2 7.2 59.6 3.2
North America 213.7 85.7 32.6 9.9
Central America 20.5 34.8 8.1 12.6
South America 84.1 50.2 29.2 16.2
Australia and New Zealand 21.0 104.2 4.0 15.4
Central and Eastern Europe 58.4 29.1 23.1 10.9
Northern Europe 64.9 73.1 17.4 15.4
Southern Europe 79.5 50.0 20.4 10.4
Western Europe 167.9 93.1 28.7 12.4
Germany 70.8 82.7 12.2 11.7
Japan 38.7 22.7 10.0 5.0
USA 186.3 83.8 28.6 9.7
Brazil 41.6 50.3 14.4 16.3
China 33.8 4.3 14.3 1.8
India 14.6 3.7 10.4 2.5
Russian Federation 22.1 26.1 9.5 10.8
SouthAfricanRepublic 7.5 59.7 2.5 20.8
Absolute numbers in thousands; ASR (W): age standardised rate per 100,000 by world standard
Table 1. Absolute numbers and age-standardised rates of incidence and mortality for selected regions and countries
[1]
Despite its high proportion of cancer diagnoses, prostate cancer is the cause of cancer specif‐
ic death in only every 16th case (258 thousand deaths, 6.1% of the total). This places prostate
cancer on the sixth position of cancer-specific causes of death, topped by lung, liver, stom‐
ach, colorectal and oesophageal cancer. These deaths occur almost equally in both, more de‐
veloped and less developed regions, thus leading to a twofold higher mortality rate in the
more developed regions.
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2.1. Incidence and mortality trends
Table 2 shows the current incidence and mortality of the USA [2], Germany [7, 8] and the
Munich Cancer Registry [4]. These rates have changed considerably over time. Time series
of more developed countries show that the incidence rates experience a drastic rise from
1985 to 1995 and remain at this high level. In the USA incidence (by world standard per
100,000) increases slowly from 1975 until 1985 (from 50 to 65). Then it rises rapidly reaching
a peak of 135 in 1992. Then it decreased, since 1995 more slowly, but it remains on a higher
level than before the peak (around 110). In Germany incidence is rising continuously since
1988 (from 30 to 75). The main explanation for these trends is the broad use of prostate spe‐
cific antigen (PSA) testing as a screening method and performing biopsies, which started in
the mid-1980s in the USA and in the early 1990s in Germany.
USA
(SEER, NCHS)
[2, 6]
Germany
(RKI)
[7, 8]
MCR
[4]
Absolute incidence 241.7 70.8 2.9
Crude incidence 157.7 145.1
Incidence ASR (W) 106.1 82.7 76.4
Mortality ASR (W) 10.2 11.7 13.3*
Lifetime risk(%) 16.2 13.0
Median age at diagnosis(years) 67.0 69.5 67.2
Median age at death(years) 80.0 76.7
5-year overall survival(%) 77.0 79.2
5-year relative survival(%) 99.2 92.0 93.4
10-year overall survival(%) 58.2
10-year relative survival(%) 98.3 87.8
Absolute numbers in thousands
ASR (W): age standardised rate per 100,000 by world standard
Incidence and mortality from cohorts of 2008 (all regions)
Absolute incidence numbers of the USA are estimates of SEER data from 2012
* Mortality ASR (W) for singular prostate cancers is 9.9
median ages from cohorts of 2005-2009 (all regions)
5-year survival from cohorts of 2002-2008 (SEER and MCR)
10-year survival from cohorts of 1998-2008 (SEER and MCR)
Table 2. Epidemiologic basic numbers
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In the USA, mortality initially increases slightly from 1975 and since 1992 it is decreasing
more rapidly (from 14 over 17 to 10). In Germany the mortality rate (by world standard per
100,000) stays stable at 13.
2.2. Age distribution and age-specific incidence and mortality rate
Nearly all patients (≈ 99%) who are diagnosed with prostate cancer have reached an age of fif‐
ty or higher. The age distribution at diagnosis describes a positively skewed unimodal distri‐
bution with its modus at the age group 65-69. This age group contributes to nearly 25% of all
prostate cancer cases. The risk of getting prostate cancer increases nearly exponentially with
increasing age. This makes prostate cancer one of the most distinctive cancers in aging popu‐
lations (Figure 1) with a ASIR of 800-1000 per 100,000 in the elderly of 70 years and older.
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Figure 1. Age distribution at diagnosis and age-specific incidence rate (ASIR) of prostate cancer (1998-2008) [4]
Nearly all patients who died of prostate cancer (singular initial malignoma) have reached an
age of fifty-five or higher. The distribution of age at death describes a negatively skewed un‐
imodal distribution with its modus at the highest age group 85+. Here the age-specific mortal‐
ity rates (ASMR) can perfectly be described by an exponential function. The risk of dying by
prostate cancer increases accelerated with increasing age (Figure 2). The ASMR reaches 450
per 100,000 for men with an age of 80-84 and already 600 per 100,000 for men older than 84.
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Figure 2. Age distribution at death and age-specific mortality rate (ASMR) of prostate cancer (1998-2009) [4]
3. Prognostic factors
According to Table 3 the conditional age distributions of the combined T categories 2 until 4
have the same shape and the modus at the age group of 65 until 69. These distributions are
shifted slightly towards higher ages with the increasing T category. This simply reflects that
it takes time to develop an advanced tumour. However, in those patients diagnosed with T1
category (clinically) the age distribution appears to be totally different. Here 80% of the men
are older than 64 (about 60% within the other T categories) and every third man is older
than 74.
Lymph node category (N), distant primary metastases (M), Gleason Score, initial PSA value
and Gleason Score are positively correlated with the combined T category: the higher the T
category, the higher the PSA value, the higher the Gleason Score and the higher the porpor‐
tion of regional or distant metastases.
A positive lymph node status is mostly diagnosed when the tumour has spread through the
prostatic capsule. Nearly 20% of those men with T3 and almost 50% with T4 tumours there‐
fore are diagnosed with lymph node metastasis.
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T category
All
%
(n=13712
100%)
T1
%
(n=1826
13.3%)
T2
%
(n=8219
59.9%)
T3
%
(n=3164
23.0%)
T4
%
(n=503
3.7%)
Age (years)
0.5 2.3 1.4 1.8 1.8<50
50 - 54 1.5 4.5 3.5 3.0 3.8
55 - 59 3.0 11.0 10.2 11.1 9.8
60 - 64 9.7 20.2 18.2 15.1 18.2
65 - 69 20.9 31.4 32.8 26.4 30.1
70 - 74 26.1 20.2 23.1 19.7 21.7
≥75 38.3 10.4 10.8 22.9 14.7
Lymph node status
2.5 1.6 18.4 45.1 7.3N+
N0 40.6 85.2 73.5 33.6 76.2
NX 56.9 13.2 8.1 21.2 16.5
Metastasis status
97.4 98.8 95.4 72.6 96.9M0
M1 2.6 1.2 4.6 27.4 3.1
PSA value (ng/ml)
25.8 13.2 7.8 3.7 13.2< 4
4 - <10 42.0 60.7 41.5 18.9 52.4
10 - <20 17.5 18.3 24.9 15.7 19.7
≥20 14.7 7.8 25.7 61.8 14.8
Gleason Score
14.3 1.6 0.2 0.2 2.92 - 4
5 - 6 54.8 48.1 12.3 4.2 39.1
7 19.1 40.5 49.4 26.6 39.3
8 - 10 11.8 9.8 38.2 68.9 18.7
Presented numbers are column-wise percentages.
T category is a combination of cT and pT.
The disease cohort is limited to 2005-2009 to provide best current estimators.
Table 3. Prognostic factors by T category [4]
Advances in Prostate Cancer8
Although, only 2.4% of all prostate cancer cases have primary distant metastases, already
25% of the T4 patients are diagnosed with metastases.
About 50% of the men with prostate cancer have a PSA value of 4 to 10 ng/ml at initial diag‐
nosis.
According to Figure 3aa shift from capsule exceeding tumours to capsule limited tumours
took place in the 1990s. In the late 1980s about 15% of the diagnosed tumours were staged
T4, some 45% T3 and nearly 25% T2. In the 2000s only some 5% of the diagnosed tumours
were staged T4, good 20% T3 and about 60% T2. The T1 category was unaffected and oscil‐
lated around 12% during the whole time period. It seems that PSA-Screening has considera‐
bly lowered the proportion of locally advanced tumours.
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Figure 3. Distribution of T category over time (n = 35544) [4]. T category is a combination of cT and pT.
4. Therapy
Table 4 presents in detail the effects of combined T category on the choice of therapy. Guide‐
lines [9] note that radical prostatectomy, radiation therapy and hormone therapy in combi‐
nation with radiation therapy are the main primary treatment options when the tumour
remains within the prostate capsule (T2) or does not invade nearby structures other than the
seminal vesicles or the bladder neck (T3). A spreading prostate cancer should be treated
with a hormone therapy. Active surveillance (AS) and watchful waiting (WW) are only note‐
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worthy initial therapy strategies for tumours detected in an early stage. Although these are
accepted treatment options in localised prostate cancer, they are seldom chosen compared to
radical prostatectomy and hormone therapy. Transurethral resection of the prostate is not an
appropriate surgical treatment option in prostate cancer but its proportion in T1 category
(46.7%) indicates a greater proportion of incidentally found prostate cancers during a treat‐
ment of benign hyperplasia. Without further surgical or hormone therapy, one could classi‐
fy these cases into the AS or WW groups.
T category
All
%
(n=13712
100%)
T1
%
(n=1826
13.3%)
T2
%
(n=8219
59.9%)
T3
%
(n=3164
23.0%)
T4
%
(n=503
3.7%)
Initial therapy
74.9 65.9 31.3 61.8RPE
TUR 47.2 3.2 2.5 11.4 9.0
HIFU 4.5 3.4 0.8 0.2 2.8
XRT 16.6 6.1 9.8 12.7 8.5
Hormone 23.7 11.6 20.3 44.2 16.4
AS and WW 8.0 0.8 0.7 0.2 1.6
Presented numbers are column-wise percentages.
T category is a combination of cT and pT.
The disease cohort is limited to 2005-2009 to provide best current estimators.
RPE: radical prostatectomy, TUR: transurethral resection of the prostate, HIFU: high-intensity focused ultrasound, XRT:
radiation therapy, Hormone: hormone therapy, AS: active surveillance, WW: watchful waiting
Table 4. Initial therapy by T category [4]
As Figure 4 shows impressively, initial therapy strategies have changed noticeably over the
last 20 years. In the late 1980’s radical prostatectomy was the initial therapy in about 25% of
all treatments. Its rate increased continuously and finally reaches almost 60%, making this
the most selected initial therapy per year since 1995. The curve of hormone therapy devel‐
oped oppositely. To be more precise: hormone therapy was the most selected treatment till
1994. From 65% in 1989 it continuously decreased to now 20%. Radiation therapy (XRT)
slightly increased to 10% as initial therapy. Finally, within the whole time span transurethral
resection of the prostate (TUR) remains stable at a proportion of nearly 10%.
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Figure 4. Distribution of initial therapy strategies over time (n = 35544) [4]. RPE: radical prostatectomy, XRT: radiation
therapy, Hormone: hormone therapy, TUR: transurethral resection of the prostate
5. Survival
The following figures mainly present the relative survival (RS) curves, an estimator for the
cancer specific survival. This is calculated by dividing the overall survival (OS) of the ob‐
served cohort by the expected survival of a normal population with the same distribution
regarding birth-date and sex.
When looking at the influence of the year of diagnosis on the overall survival (Figure 5) or
relative survival (Figure 6) only the curve of patients with a diagnosis in the years 1998 until
1992 noticeably differs from the other ones. Here the 5- and 10-year relative survival was
85.0% and 74.3%, respectively. In the group of patients diagnosed between 1993 and 1997
the 5- and 10-year relative survival was 94.9% and 88.6% in the group of 1998-2002 the 5-
and 10-year relative survival was 94.0% and 84.1% and in the recent group of 2003-2008 the
5-year relative survival was 92.1%. Therefore, the following survival analyses are presented
for patients with a diagnosis between 1998 - 2008.
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Figure 5. Overall survival by year of diagnosis (n=30902) [4]
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Figure 6. Relative survival by year of diagnosis (n=30902) [4]. Relative survival is the quotient of overall survival and
expected survival and thus an estimator for the cancer specific survival.
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The complete cohort of prostate cancer patients with a diagnosis between 1998 and 2008
(Figure 7) shows a 5-year overall survival of 78.8% and a 10-year overall survival of 57.7%.
The relative survival is 93.6% and 84.1%, respectively. For comparison: SEER data show a 5-
year relative survival of 99.2% for patients diagnosed between 2002 and 2008 and a 10-year
relative survival of 98.3% for the cohort of 1998 – 2008.
Figure 8 presents the relative survival by the combined T category. As expected, patients
with a T2-staging perform better than patients with a T1-Staging. The 5- and 10-year relative
survival is 102.0% and 94.0% in T1, 104.9% and 108.8% in T2, 97.6% and 89.5% in T3 and
61.4% and 43.8% in T4, respectively. Relative survival can exceed 100%, because prostate
cancer patients benefit from the better treatment of comorbidities during aftercare.
Lymph node status (N category) is an important prognostic factor. As Figure 9 shows, a pos‐
itive lymph node status (N+) reduces the relative survival drastically (77.7% for 5-year and
61.9% for 10-year survival) compared to a 5- and 10-year survival of 105.5% and 107.5% in
N0. Nonetheless, prostate cancer patients benefit from radical prostatectomy in the situation
with lymph node metastases [10].
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Figure 7. Overall, relative and expected survival of the complete collective (1998-2008, n = 25773) [4]. Relative survival
is the quotient of overall survival and expected survival and thus an estimator for the cancer specific survival.
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Figure 8. Relative Survival by T category (1998-2008, n = 20685) [4]. T category is a combination of cT and pT.
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Figure 9. Relative Survival by N category (1998-2008, n = 19726) [4]. N category is a combination of cN and pN.
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Figure 10. Relative survival by Gleason Score (1998-2008, n = 21759) [4]
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Figure 11. Post Progression Survival (1998-2008, n = 2223) [4]. Starting point of progression is from date of locore‐
gional relapse or distant metastasis (primary M1 or metastases in further course of disease).
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According to Figure 10 patients with the worst Gleason Score category (8 – 10) have a much
poorer survival (73.4% for five year and 55.0% for ten year survival) than patients with a scor‐
ing of 7 and better, which does not discriminate very much (104.1% and 94.8% for Gleason
Score 2 - 4, 102.2% and 98.6% for Gleason Score 5 – 6 and 98.6% and 91.8% for Gleason Score 7).
If the tumour has metastasised or locoregional recurrence has occurred, only 18.2% of the
patients survive 5 years and 7.2% of the patients survive 10 years. The median survival is
about two years (Figure 11).
Nomenclature
WHO→World Health Organization
SEER→“Surveillance, Epidemiology and End Results” Program of the National Cancer Insti‐
tute of the USA
NCHS→National Center for Health Statistics
RKI→Robert Koch Institut
MCR→Munich Cancer Registry
PSA→Prostate specific antigen
RPE→Radical prostatectomy
XRT→Radiation therapy
HIFU→High-intensity focused ultrasound
Hormone→Hormon therapy
TUR→Transurethral resection of the prostate
AS→Active surveillance
WW→Watchful waiting
ASR (W)→Age-standardised rate, using the proposed world standard population of Segi
(1960)
ASIR→Age-specific incidence rate
ASMR→Age-specific mortality rate
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